Beximco Pharmaceuticals Ltd - Bangladesh-based generic pharmaceutical products and active pharmaceutical ingredients maker - Partner Serum Institute of India Pvt Ltd's supply to Beximco of a first instalment of the Oxford University and AstraZeneca PLC Covid-19 vaccine for the Bangladesh private pay market has been delayed. The delay is attributed to "prioritisation on supplying vaccine doses for government mass vaccination programmes" as well as World Health Organisation-led initiatives over private pay use. The length of this delay, which is for the first 500,000 doses of a 1 million dose deal is not yet known, Beximco says.
Beximco already has received 5 million doses from Serum Institute of India, which Beximco is distributing in Bangladesh as part of the government's mass vaccination programme. The deal is for a total of 30 million doses, to be delivered in monthly instalments until June 2021 and distributed exclusively by Beximco.
"Beximco reiterates that the impact of importing and distributing the vaccine is still expected to have a material positive impact on the company's full year results," it says.
Current stock price: 87.01 pence
Year-to-date change: down 13%
By Anna Farley; annafarley@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)
Beximco Pharma (BXP)
